CLSD: Clearside Biomedical Inc Company Profile & Statistics

About

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.

Info & Links

CEO

George Lasezkay

Headquarters

900 NORTH POINT PARKWAY, SUITE 200
ALPHARETTA, GA 30005, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

Clearside Biomedical Inc Statistics

Valuation Measures

Market Capitalization²

75.08M

Enterprise Value

61.19M

Enterprise Value/EBITDA(ttm)

-2.47

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

10.04

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-413.83%

Profit Margin(ttm)

-3592.23%

Return on Equity(ttm)

Return on Invested Capital(ttm)

133.25%

Return on Assets(ttm)

-92.90%

Income Statement

Revenue(ttm)

7.70M

Revenue Per Share(ttm)

0.10

Gross Profit(ttm)

7.70M

EBITDA(ttm)³

-24.77M

Net Income Available to Common(ttm)

-31.88M

Diluted EPS(ttm)

-0.45

Share Statistics

Beta (5Y Monthly)

2.29

52-Week Change

-11.61%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

75.84M

Dividend Yield

0.00%

Float⁴

68.87M

% Held by Insiders

9.20%

% Held by Institutions

18.75%

Balance Sheet

Total Cash(mrq)

23.59M

Total Cash Per Share(mrq)

0.31

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

4.49%

Quick Ratio(mrq)

4.49%

Book Value Per Share(mrq)

-0.47

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.26

Free Cash Flow(ytd)

-19.98M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CLSD

Clearside Biomedical Inc

Clearside Biomedical Inc Profile